VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2017 | FCR or FR – which regimen is better for treating CLL?

Susan O’Brien, MD from the University of California, Irvine, CA provides us an overview of the current treatment of chronic lymphocytic leukemia (CLL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. The results from the CLL8 trial, in which the efficacies of FCR and FR in treating CLL patients were compared, are also mentioned here (NCT00281918). She also explains the need for validating the superiority of FCR over FR in treating CLL patients who are candidates for chemoimmunotherapy, which was evaluated in this trial.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter